The Live Nagpur
  • Nagpur City
  • Nagpur Education
  • Nagpur Sports
  • Business
  • Featured
  • Crime
  • Entertainment & Lifestyle
  • Health & Wellness
  • Nation
  • Politics
  • Trending
  • Vidarbha
  • Obituary

The Live Nagpur

  • Home
  • City
  • Politics
  • Business
  • Education
  • Entertainment
  • Sports
  • Health
  • Crime
  • Forest
  • Featured
  • Vidarbha
Health & Wellness

Phase 3 Clinical Trial of COVAXIN shows 81% efficacy

by TLN Team August 3, 2021August 3, 2021
written by TLN Team August 3, 2021August 3, 2021
Phase 3 Clinical Trial of COVAXIN shows 81% efficacy

The Phase 3 result of the COVAXIN has shown an interim vaccine efficacy of 81% in preventing Covid-19.

The Phase 3 trial was initiated in mid-November 2020, which was conducted in a total of 25,800 individuals across 21 sites. The interim efficacy trend of 81%, analyzed as per the protocol approved by the DCGI, puts it at par with other global front-runner vaccines.

“The bench-to-bedside journey of completely indigenous COVID-19 vaccine in less than 8 months’ time showcases the immense strength of Atmanirbhar Bharat [self-reliant India] to fight the odds and stand tall in the global public health community. It is also a testament to India’s emergence as a global vaccine superpower,” said Dr. Balram Bhargava, Director General, ICMR.

The COVAXIN is the first COVID-19 vaccine that has been developed completely in India. In March 2020, following the successful isolation of the SARS CoV-2 virus at ICMR-National Institute of Virology (NIV), ICMR entered into a public-private partnership with BBIL to develop the virus isolate into an effective vaccine candidate.

ICMR-NIV characterized the vaccine developed by BBIL through in-vitro experiments and electron microscopy studies.

Pre-clinical studies in small animals and hamsters showed promising results in terms of safety and immunogenicity. Further studies conducted in rhesus macaques also established remarkable safety and protective efficacy of COVAXIN. Phase 1 and Phase 2 clinical trials conducted in 755 participants demonstrated high safety profile of the candidate vaccine with seroconversion rates of 98.3% and 81.1% on day 56 and 104 respectively.

COVAXIN has been developed on the WHO prequalified vero cell platform, which is globally recognized with a well-established track record of safety. COVAXIN’s ability to neutralize UK variant strain of SARS-CoV-2 has also recently been established. “The development and deployment of COVAXIN ensures that India has a powerful weapon in its arsenal in a continually evolving pandemic situation and will go a long way in helping us win the war against COVID-19. The need of the hour is to ensure that people in India continue to receive the vaccine and break the chain of virus transmission,” said Dr. Samiran Panda, Head, Epidemiology and Communicable Disease, ICMR and Director, National AIDS Research Institute.

0 comment
FacebookTwitterLinkedin
TLN Team

previous post
CBSE Class X result declared, 99.04% pass percent
next post
UGC declares 24 fake institutes, one from Nagpur

You may also like

Special on the occasion of World Alzheimer’s Day...

September 21, 2023

Heartfulness App is the Only Meditation App Supporting...

September 12, 2023

 Let’s eat and Celebrate:  World Samosa Day

September 5, 2023

Ahar Jagar and Breast Cancer Awareness Program under...

September 4, 2023

Alarming Condition: 3,000 Dengue Suspects in the City

August 30, 2023

Common Mistakes When Buying ULIP Schemes

August 29, 2023

Rule for doctors to prescribe generic drugs put...

August 25, 2023

5 Health Benefits of Ashwagandha

August 23, 2023

Only registered Sonography Centres allowed to operate: CS

August 21, 2023

1245 suspected Dengue patients found in the Last...

August 19, 2023

Trending News

  • Heavy Rain – Alert by NMC

    September 23, 2023
  • Holiday announced for schools & colleges in Nagpur district

    September 23, 2023
  • DCM Devendra Fadnavis is continuously monitoring the heavy rain situation in Nagpur.

    September 23, 2023
  • Streets, Houses Submerged After Heavy Rain In Nagpur

    September 23, 2023
  • National Cinema Day will allow viewers to watch movies for Rs99 per admission

    September 22, 2023

Important Links

  • Politics
  • Crime
  • Business
  • Education
  • Entertainment
  • Sports

Available on Playstore & Coming Soon on Appstore

Sign-Up Form

Subscribe my Newsletter for new blog posts, tips & new photos. Let's stay updated!

Footer Logo
  • Nagpur City
  • Nagpur Education
  • Nagpur Sports
  • Business
  • Featured
  • Crime
  • Entertainment & Lifestyle
  • Health & Wellness
  • Nation
  • Politics
  • Trending
  • Vidarbha
  • Obituary
  • Privacy Policy
  • Cookie Policy
  • Terms Of Use
  • Advertise with Us

© 2020 - The Live Nagpur . All Rights Reserved.